Fecal elimination of metabolites also occurs, particularly following oral administration, though quantitative contribution of each elimination pathway varies by route and dose
Dosage protocols for injectable GHK-Cu, BPC-157, and TB-500 blends typically include 200-300 mcg/day for GHK-Cu, 250-500 mcg/day for BPC-157, and 750 mcg twice weekly for TB-500
Please reference the following link to learn more
And to understand how the peptide side is designed and overseen, read our overview of physician supervised peptide therapy in Miami and Doral, how a protocol is built around your goals, and why medical oversight matters so much
In preclinical models, BPC-157 is investigated for its activity across several interconnected signaling cascades, including the VEGFR2/eNOS angiogenic axis, the FAK-paxillin pathway in tendon fibroblasts, and ERK1/2-mediated transcription factor activation